The Role of Sulfur Amino Acids in Risk of Kwashiorkor

April 26, 2018 updated by: Tufts University
This observational cross-sectional study is investigating if young children in populations with higher prevalence of kwashiorkor malnutrition have lower dietary sulfur amino acid intake than populations with lower prevalence of kwashiorkor, controlling for multiple potential confounding factors. Intake is estimated through diet recalls during interviews with a child's caregiver, analysis of urine samples and analysis of food samples for their amino acid profiles.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Kwashiorkor is one of two categorizations of severe acute malnutrition, but its etiology remains unclear. Although kwashiorkor is found only where diets are low in quality protein, comparisons of total dietary protein of individual children with and without kwashiorkor has been inconclusive. This study aims to compare amino acid profiles of the diets, not just total protein.

Evidence has shown that children with kwashiorkor consistently have very low circulating levels of sulfur amino acids (cysteine and methionine). Typical staple foods in regions with endemic kwashiorkor are generally poor in sulfur amino acids and the signs characterizing kwashiorkor can plausibly be explained by a shortage of sulfur amino acids.

In eastern Democratic Republic of the Congo, certain populations have chronically higher prevalence of kwashiorkor than neighboring populations with similar livelihoods, religion, environment, language and ethnicity. This study will compare these two populations to understand what differences between them may explain the difference in prevalence.

Study Type

Observational

Enrollment (Actual)

360

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 3 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The study population, both groups, live within a 3 mile by 3 mile square in rural eastern Democratic Republic of the Congo.

Description

Inclusion Criteria:

  • resident of the selected population
  • in the appropriate age range

Exclusion Criteria:

  • caregiver reports the child has an illness that has required treatment for at least 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
High Prevalence Population
Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is >2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
no intervention
Low Prevalence Population
Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is <2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dietary sulfur amino acid
Time Frame: one measure at one time point within three weeks of registration
mg of sulfur amino acid in the diet per kg of body weight
one measure at one time point within three weeks of registration
dietary sulfur amino acid above or below WHO estimated average requirement (EAR)
Time Frame: one measure at one time point within three weeks of registration

the total sulfur amino acid in the diet will be calculated from a diet recall

this will be a bivariate measure, "1" if the SAA in the diet is above or "0" if below the WHO/FAO requirement for sulfur amino acid intake of 17mg of sulfur amino acids per kg of body weight per day

one measure at one time point within three weeks of registration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
calories and protein in diet per kg of body weight
Time Frame: one measure at one time point within three weeks of registration

intake of calories (kcal/kg body weight),

digestibility adjusted protein - sum of (grams of protein per food item x digestibility of food item) per kg of body weight

quality adjusted protein = digestibility adjusted protein in the diet x proportion of requirement of the limiting amino acid

one measure at one time point within three weeks of registration
urinary sulfate
Time Frame: one measure at one time point within three weeks of registration
sulfate excreted in the urine, normalized to creatinine
one measure at one time point within three weeks of registration

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
urinary thiocyanate
Time Frame: one measure at one time point within three weeks of registration
thiocyanate excreted in the urine (ppm)
one measure at one time point within three weeks of registration
socio-environmental factors (use of a latrine, shelter description, feeding habits, household demographics, health history)
Time Frame: one measure at one time point within three weeks of registration
sanitation - does the child use a latrine, defecate in the woods/fields, defecate around the home shelter - materials used for the roof and walls, size of the home in square meters feeding habits - number of hot meals per day, number of feeding episodes per day household demographics - age and sex of all people who eat and sleep regularly at that homestead health history - illnesses in the past 30 days, previous diagnoses of malnutrition and type of malnutrition
one measure at one time point within three weeks of registration
physical measurements of the subject's body size
Time Frame: one measure at one time point within three weeks of registration
height to the nearest mm, weight to the nearest 100g, middle-upper arm circumference to the nearest mm, visual signs of kwashiorkor (edema, rough or darkened skin, friable lightened hair, distended abdomen, lethargy or irritability)
one measure at one time point within three weeks of registration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Daniel Maxwell, PhD, Tufts University, Friedman School

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2016

Primary Completion (Actual)

August 14, 2016

Study Completion (Actual)

August 2, 2017

Study Registration Dates

First Submitted

April 17, 2018

First Submitted That Met QC Criteria

April 26, 2018

First Posted (Actual)

May 11, 2018

Study Record Updates

Last Update Posted (Actual)

May 11, 2018

Last Update Submitted That Met QC Criteria

April 26, 2018

Last Verified

April 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 1605004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kwashiorkor

Clinical Trials on No intervention

3
Subscribe